JAK/BCL2 Inhibition Acts Synergistically with LSD1 Inhibitors to Selectively Target ETP-ALL

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2022 Oct 13

PMID 36229595

Authors

Aissa Benyoucef

Katharina Haigh

Andrew Cuddihy

Jody J Haigh

Affiliations

Soon will be listed here.

Abstract

ETP-ALL (Early T cell Progenitor Acute Lymphoblastic Leukemia) represents a high-risk subtype of T cell acute lymphocytic leukemia (T-ALL). Therapeutically, ETP-ALL patients frequently relapse after conventional chemotherapy highlighting the need for alternative therapeutic approaches. Using our ZEB2 ETP-ALL mouse model we previously documented the potential utility of the catalytic LSD1 inhibitor (GSK2879552) for treating mouse/human ETP-ALL. However, this approach proved to be inefficient, especially in killing human LOUCY cell ETP-ALL xenografts in vivo. Here we have revealed the novel involvement of ZEB2/LSD1 complexes in repressing the intrinsic apoptosis pathway by inhibiting the expression of several pro-apoptotic proteins such as BIM (BCL2L11) as a major driver for ETP-ALL survival. Treatment with LSD1i (particularly with the steric inhibitor SP2509) restored the expression of ZEB2/LSD1 pro-apoptotic BIM (BCL2L11) target. In combination with a JAK/STAT pathway inhibitor (JAKi, Ruxolitinib) or with a direct inhibitor of the anti-apoptotic BCL2 protein (BCL2i, ABT-199) resistance of human and mouse ETP-ALL to LSD1i was reversed. This new combination approach efficiently inhibited the growth of human and mouse ETP-ALL cells in vivo by enhancing their differentiation and triggering an apoptotic response. These results set the stage for novel combination therapies to be used in clinical trials to treat ETP-ALL patients.

Citing Articles

Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia.

Tremblay C, Saw J, Yan F, Boyle J, Amarasinghe O, Abdollahi S Leukemia. 2025; 39(3):577-589.

PMID: 39849166 PMC: 11879882. DOI: 10.1038/s41375-024-02491-5.

Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.

The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression.

Cuevas D, Amigo R, Agurto A, Heredia A, Guzman C, Recabal-Beyer A Biomedicines. 2024; 12(8).

PMID: 39200378 PMC: 11351244. DOI: 10.3390/biomedicines12081915.

JAK/STAT in leukemia: a clinical update.

Liang D, Wang Q, Zhang W, Tang H, Song C, Yan Z Mol Cancer. 2024; 23(1):25.

PMID: 38273387 PMC: 10811937. DOI: 10.1186/s12943-023-01929-1.

An "unexpected" role for EMT transcription factors in hematological development and malignancy.

Radhakrishnan K, Truong L, Carmichael C Front Immunol. 2023; 14:1207360.

PMID: 37600794 PMC: 10435889. DOI: 10.3389/fimmu.2023.1207360.

References

Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, Hadler M, Paietta E, Tallman M . Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood. 2013; 122(1):74-82. PMC: 3701905. DOI: 10.1182/blood-2013-03-491092. View

Coustan-Smith E, Mullighan C, Onciu M, Behm F, Raimondi S, Pei D . Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10(2):147-56. PMC: 2840241. DOI: 10.1016/S1470-2045(08)70314-0. View

Zuurbier L, Gutierrez A, Mullighan C, Cante-Barrett K, Gevaert A, de Rooi J . Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica. 2013; 99(1):94-102. PMC: 4007923. DOI: 10.3324/haematol.2013.090233. View

Zhang J, Ding L, Holmfeldt L, Wu G, Heatley S, Payne-Turner D . The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380):157-63. PMC: 3267575. DOI: 10.1038/nature10725. View

Eppert K, Takenaka K, Lechman E, Waldron L, Nilsson B, van Galen P . Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011; 17(9):1086-93. DOI: 10.1038/nm.2415. View

Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S . ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun. 2015; 6:5794. PMC: 4354161. DOI: 10.1038/ncomms6794. View

Li H, Mar B, Zhang H, Puram R, Vazquez F, Weir B . The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood. 2016; 129(4):497-508. PMC: 5270388. DOI: 10.1182/blood-2016-05-714493. View

Goossens S, Wang J, Tremblay C, Medts J, TSas S, Nguyen T . ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms. Haematologica. 2019; 104(8):1608-1616. PMC: 6669144. DOI: 10.3324/haematol.2018.207837. View

Inukai T, Kiyokawa N, Campana D, Coustan-Smith E, Kikuchi A, Kobayashi M . Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol. 2011; 156(3):358-65. DOI: 10.1111/j.1365-2141.2011.08955.x. View

10.

Jain N, Lamb A, OBrien S, Ravandi F, Konopleva M, Jabbour E . Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016; 127(15):1863-9. PMC: 4915808. DOI: 10.1182/blood-2015-08-661702. View

11.

Goossens S, Peirs S, Van Loocke W, Wang J, Takawy M, Matthijssens F . Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia. Blood. 2017; 129(8):981-990. PMC: 5783288. DOI: 10.1182/blood-2016-06-721191. View

12.

Cui H, Bansal V, Grunert M, Malecova B, DallAgnese A, Latella L . Muscle-relevant genes marked by stable H3K4me2/3 profiles and enriched MyoD binding during myogenic differentiation. PLoS One. 2017; 12(6):e0179464. PMC: 5469484. DOI: 10.1371/journal.pone.0179464. View

13.

Orford K, Kharchenko P, Lai W, Dao M, Worhunsky D, Ferro A . Differential H3K4 methylation identifies developmentally poised hematopoietic genes. Dev Cell. 2008; 14(5):798-809. PMC: 10948009. DOI: 10.1016/j.devcel.2008.04.002. View

14.

Fang Y, Liao G, Yu B . LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019; 12(1):129. PMC: 6894138. DOI: 10.1186/s13045-019-0811-9. View

15.

Wu B, Pan X, Chen X, Chen M, Shi K, Xu J . Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy. Signal Transduct Target Ther. 2019; 4:11. PMC: 6483994. DOI: 10.1038/s41392-019-0040-2. View

16.

Harris W, Huang X, Lynch J, Spencer G, Hitchin J, Li Y . The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012; 21(4):473-87. DOI: 10.1016/j.ccr.2012.03.014. View

17.

Buffiere A, Uzan B, Aucagne R, Hermetet F, Mas M, Nassurdine S . T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7. Oncogene. 2019; 38(48):7357-7365. DOI: 10.1038/s41388-019-0921-4. View

18.

Silva A, Laranjeira A, Martins L, Cardoso B, Demengeot J, Yunes J . IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 2011; 71(14):4780-9. DOI: 10.1158/0008-5472.CAN-10-3606. View

19.

McLean C, Bristor D, Hiller M, Clarke S, Schaar B, Lowe C . GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010; 28(5):495-501. PMC: 4840234. DOI: 10.1038/nbt.1630. View

20.

Mascarenhas J, Hoffman R . Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012; 18(11):3008-14. DOI: 10.1158/1078-0432.CCR-11-3145. View